Selecta Biosciences and Sanofi sign global collaboration


Selecta Biosciences Inc., a Watertown biopharmaceutical company specializing in synthetic vaccines and immunotherapies, said Wednesday that it has entered into a strategic global collaboration with Sanofi SA, the French drug maker that recently bought Cambridge-based Genzyme.

The collaboration between Selecta and Sanofi seeks to discover highly targeted immunotherapies for life-threatening allergies.

“Under the terms of the agreement Selecta is eligible to receive several pre-clinical, clinical, regulatory, and sales milestones totaling $300 million per allergen indication for up to three immunotherapy candidates contemplated by this collaboration,” the companies said in a press release. “Selecta is also entitled to up to double digit tiered royalties as percentage of product net sales for each commercialized immunotherapy.”

Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.